How Flibanserin works
Reading File
Searching the Web
flibanserin mechanism of action HSDD 2025
Finding Sources
Reading Web Page
https://www.ncbi.nlm.nih.gov/books/NBK589649
Reading File
Reading File
Here is a detailed breakdown of how flibanserin works:
Flibanserin (Addyi) - Mechanism of Action
Background
Flibanserin was originally developed as an antidepressant, but was repurposed after researchers noticed it affected sexual desire. It was FDA-approved in 2015 as the first drug for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women - a condition defined as persistently low sexual desire causing significant personal distress.
The Neurobiology of Sexual Desire
Sexual desire is governed by a balance of two competing systems in the brain:
| Factor | Effect on Libido |
|---|---|
| Dopamine (DA) | Positive - promotes desire |
| Norepinephrine (NE) | Positive - promotes desire |
| Estrogen, Testosterone | Positive |
| Serotonin (5-HT) | Negative - inhibits desire |
| Prolactin | Negative - inhibits desire |
In HSDD, the theory is that this balance is disrupted - too much serotonin activity and not enough dopamine/norepinephrine in key brain circuits.
Flibanserin's Receptor Actions
Flibanserin is classified as a Multifunctional Serotonin Agonist and Antagonist (MSAA). It acts on postsynaptic serotonin receptors (unlike buspirone, which works presynaptically):
| Receptor | Action | Effect |
|---|---|---|
| 5-HT1A | Full agonist | Activating these receptors reduces serotonin's libido-suppressing effect |
| 5-HT2A | Antagonist | Blocks serotonin signaling that inhibits desire |
| 5-HT2B / 5-HT2C | Moderate antagonist | Secondary effects, likely not clinically dominant |
| Dopamine D4 | Weak partial agonist | Minor contribution to dopaminergic effect |
The Downstream Effect: The Prefrontal Cortex Shift
The drug's primary site of action is the prefrontal cortex. Here's the chain of events:
- Flibanserin activates postsynaptic 5-HT1A receptors and blocks 5-HT2A receptors on pyramidal neurons
- These pyramidal neurons excite brainstem 5-HT neurons but inhibit brainstem dopamine and norepinephrine neurons
- The net result:
- Serotonin levels decrease in the prefrontal cortex
- Dopamine and norepinephrine levels increase in the prefrontal cortex
This rebalancing of monoamines shifts the brain's sexual motivation circuitry toward desire.
"This action in the prefrontal cortex causes the downstream release of dopamine and norepinephrine and reduction of serotonin."
- Harrison's Principles of Internal Medicine, 22E
Key Pharmacokinetic Points
- Dose: 100 mg taken at bedtime (once daily)
- Half-life: ~11 hours
- Onset: Gradual; maximum efficacy around 8 weeks - discontinue if no effect by then
- Protein binding: ~98% (mostly albumin)
- Important interaction: Alcohol dramatically increases risk of hypotension and syncope. Take at least 2 hours apart from alcohol consumption (earlier REMS restrictions were later relaxed based on postmarketing studies)
What Makes It Different
- It does not act like SSRIs (which worsen sexual desire by flooding serotonin)
- It is not addictive - it does not alter dopamine in the nucleus accumbens (the reward/addiction center)
- It acts centrally (in the brain), unlike PDE-5 inhibitors (e.g. Viagra) which act peripherally on blood vessels
- Its exact mechanism in humans is still labeled "not fully known" by the FDA, since the precise neural circuits in women remain incompletely mapped
Efficacy
Roughly 50% of women with HSDD respond to flibanserin. It increases the number of satisfying sexual events and reduces distress related to low desire.
The FDA-approved label itself notes: "The mechanism of action of ADDYI in the treatment of HSDD is not known" - reflecting that while we understand its receptor pharmacology well, the complete clinical translation remains an active area of research.
- Harrison's Principles of Internal Medicine, 22E
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry
- StatPearls - Flibanserin (NCBI Bookshelf)
Can flibanserin work in men vriab
Finding Sources
Searching PubMed
flibanserin male sexual desire disorder men
Searching the Web
flibanserin use in men HSDD male evidence research
Reading Article
PMID: 20646181
Here is a thorough answer to whether flibanserin can work in men:
Flibanserin in Men - What the Evidence Says
Official Status: Not Approved
Flibanserin is not FDA-approved for men and is not indicated for male HSDD. Current textbooks explicitly state it is "not indicated... in men" (Current Psychiatry/MDedge). All three pivotal Phase III trials that led to its 2015 approval enrolled only premenopausal women.
Why It Could Theoretically Work in Men
The neurobiological basis for HSDD - a serotonin/dopamine imbalance in sexual desire circuits - is not sex-specific. Men also experience low sexual desire driven by the same neurotransmitter systems:
- Excess serotonin suppresses libido in men just as in women
- Dopamine and norepinephrine promote sexual motivation in both sexes
- The prefrontal cortex circuits flibanserin targets exist identically in men
There is no compelling biological reason why the mechanism would be exclusive to women.
Early Hints from Male Subjects
The earliest flibanserin research actually included men. In the original antidepressant trials (Kennedy, J Sex Med, 2010 - PMID 20646181):
- 369 men and 523 women with Major Depressive Disorder were enrolled
- At baseline, 38% of men reported sexual dysfunction (vs. 67% of women)
- Flibanserin showed sexual function improvements, though results were inconsistent across studies
- The study was not powered to draw conclusions about men specifically
These trials revealed signal in women, which redirected development entirely toward HSDD in women.
Current Off-Label Evidence in Men
The evidence in men is sparse but emerging:
| Study Type | Finding |
|---|---|
| Small retrospective series (26 men) | No new safety concerns identified |
| Real-world survey | 69% of men who took flibanserin for ≥2 months reported improved desire and orgasm |
| Alcohol interaction studies | Originally tested in young healthy men - showed hypotension risk with alcohol |
Active Clinical Trial (2025-2026)
The most significant development is an ongoing Phase 2 randomized controlled trial at Baylor College of Medicine, led by Dr. Mohit Khera:
- 60 men with HSDD randomized to flibanserin 100 mg nightly vs. placebo
- Eligibility: normal testosterone, no erectile dysfunction, stable relationship
- Expected completion: 2026
- This will be the first high-quality controlled data on flibanserin efficacy in men
Practical Considerations for Off-Label Use
If a clinician were to consider it in a man with HSDD:
- Dose would be the same: 100 mg nightly (only tested dose)
- Same interactions apply: alcohol, CYP3A4 inhibitors (fluconazole, some SSRIs) - risk of hypotension
- Same 8-week trial period applies before judging efficacy
- Not appropriate if low testosterone or erectile dysfunction is the primary issue - those have better-evidenced treatments
Bottom Line
Flibanserin could plausibly work in men through the same central serotonin-dopamine mechanism, and limited off-label data is cautiously encouraging. However, no controlled trial has yet confirmed efficacy in men. The Baylor Phase 2 trial expected to complete in 2026 will be the first real answer. Until then, it remains an off-label use with very limited supporting evidence - not a standard-of-care option for men.
What are the approved treatments for low sexual desire in men?
Finding Sources
Searching PubMed
hypoactive sexual desire disorder men treatment
Searching the Web
FDA approved treatments low sexual desire men HSDD 2025
Finding Sources
Reading Article
PMID: 34183196
Reading Web Page
https://www.renalandurologynews.com/news/fda-signals-support…
Finding Sources
Reading File
Here is a complete, evidence-based overview:
Approved & Evidence-Based Treatments for Low Sexual Desire in Men
The Core Problem: No Drug Approved Specifically for Male HSDD
Unlike in women (where flibanserin and bremelanotide are FDA-approved for HSDD), there is no drug with a specific FDA approval for low sexual desire as an isolated diagnosis in men. Treatment is guided by identifying and addressing the underlying cause.
1. Testosterone Replacement Therapy (TRT) - The Primary Approved Option
TRT is the closest thing to an approved treatment for low libido in men, specifically when confirmed hypogonadism is present.
Current FDA approval: TRT is approved for testosterone deficiency due to structural or genetic causes (primary or secondary hypogonadism - e.g. Klinefelter syndrome, pituitary failure, orchidectomy).
Evolving FDA stance (2025): The FDA has recently signaled it is encouraging TRT manufacturers to pursue a new expanded indication - treating low libido in men with idiopathic hypogonadism (age-related testosterone decline without a clear structural cause). The pivotal TRAVERSE trial (5,204 men) included a sexual function sub-study confirming TRT improves libido scores. Manufacturers must submit supplemental NDAs with clinical data.
How it works for libido:
"Testosterone regulates sexual desire and modulates almost every component involved in erectile function... Testosterone improves libido in men with low testosterone levels."
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry
Diagnosis threshold: Serum testosterone consistently below 8 nmol/L (231 ng/dL) at 8-10 AM on three occasions.
Target range: 13.9-27.0 nmol/L (400-700 ng/dL)
Available formulations:
| Formulation | Notes |
|---|---|
| Topical gel/solution | Most common; daily application |
| Transdermal patch | Convenient; skin irritation possible |
| Intramuscular injection | Every 2-4 weeks; cost-effective |
| Subcutaneous implant (pellet) | Long-acting; every 3-6 months |
| Oral tablet (e.g. testosterone undecanoate) | Newer option; taken with meals |
| Buccal tablet | Twice daily |
Contraindications: History of prostate cancer, breast cancer.
Key side effects: Erythrocytosis (elevated hematocrit), worsening benign prostatic hyperplasia, obstructive sleep apnea exacerbation, venous thromboembolism, reduced sperm production/fertility.
2. Treating Underlying Medical Causes
Many cases of low male libido are secondary to treatable conditions. Addressing these is first-line before adding drugs:
| Cause | Treatment |
|---|---|
| Hypogonadism | TRT (as above) |
| Hyperprolactinemia | Dopamine agonists (cabergoline, bromocriptine) |
| Hypothyroidism | Levothyroxine |
| Depression | Antidepressants (note: SSRIs can worsen libido - bupropion preferred) |
| SSRI-induced sexual dysfunction | Switch to bupropion, add bupropion, or dose reduction |
| Opioid-induced androgen deficiency | TRT - RCTs confirm improved sexual desire and quality of life |
| Relationship/psychological factors | Sex therapy, couples counseling |
3. Off-Label Options Used in Practice
When TRT is not appropriate or hypogonadism is absent:
- Bupropion - dopamine/norepinephrine reuptake inhibitor; off-label for low desire; evidence in women is stronger but used in men too
- Bremelanotide (Vyleesi) - approved only for women, but off-label case series in men show ~39% HSDD improvement and improvements in 91% of men in one series (desire, arousal, confidence)
- Flibanserin - off-label; Phase 2 trial in men (Baylor College, 60 men) expected to report in 2026
4. Non-Pharmacological Approaches
Guidelines (EAU 2021, PMID 34183196) recommend these alongside or before drug therapy:
- Psychosexual therapy / sex therapy - particularly for lifelong or psychogenic HSDD
- Lifestyle modification - exercise, weight loss, reducing alcohol, improving sleep
- Couples therapy - relationship conflict is a major driver of low desire in men
- Screening and treating cardiovascular risk - metabolic syndrome and atherosclerosis impair desire and arousal
Summary Table
| Treatment | Regulatory Status | Best for |
|---|---|---|
| Testosterone (TRT) | FDA-approved (hypogonadism) | Low T confirmed on labs |
| Cabergoline | FDA-approved (hyperprolactinemia) | Elevated prolactin |
| Levothyroxine | FDA-approved (hypothyroidism) | Low thyroid |
| Bupropion | Off-label | SSRI-induced or idiopathic |
| Bremelanotide | Off-label in men | Complex desire/arousal disorders |
| Flibanserin | Off-label, investigational | Awaiting 2026 trial data |
| Psychotherapy | Non-drug standard of care | Psychogenic, relationship-based |
The bottom line is that in men, treating the cause (especially confirming or excluding hypogonadism) is the first step. A drug approved specifically for idiopathic male HSDD, analogous to flibanserin for women, does not yet exist - though the FDA's recent encouragement around TRT label expansion and ongoing flibanserin trials suggest this gap may close in coming years.
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry
- Campbell-Walsh-Wein Urology
- EAU Guidelines on Male Sexual Dysfunction 2021 (PMID 34183196)
List all psychiatric drugs similar to tianeptine
Asking for Preferences
Finding Sources
Finding Sources
Searching the Web
tianeptine antidepressant drugs same indication depression anxiety complete list 2025
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC12506068
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I now have comprehensive data from medical textbooks and recent systematic reviews. Here is the complete list:
Psychiatric Drugs Used for Depression and Anxiety (Same Clinical Use as Tianeptine)
Tianeptine is used for major depressive disorder (MDD) and anxiety disorders. Below are all major drug classes and individual agents used for the same indications.
1. Selective Serotonin Reuptake Inhibitors (SSRIs)
The most commonly prescribed antidepressants globally; also first-line for most anxiety disorders.
| Drug | Brand Name |
|---|---|
| Fluoxetine | Prozac |
| Sertraline | Zoloft |
| Escitalopram | Lexapro |
| Citalopram | Celexa |
| Paroxetine | Paxil |
| Fluvoxamine | Luvox |
2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Block both serotonin and norepinephrine reuptake; also effective for anxiety, chronic pain, and fibromyalgia.
| Drug | Brand Name |
|---|---|
| Venlafaxine | Effexor XR |
| Desvenlafaxine | Pristiq |
| Duloxetine | Cymbalta |
| Levomilnacipran | Fetzima |
| Milnacipran | Savella (approved for fibromyalgia in US; used as antidepressant in Europe) |
3. Tricyclic Antidepressants (TCAs)
Tianeptine's own structural class. Older drugs with broader receptor activity; used when SSRIs/SNRIs fail.
| Drug | Brand Name |
|---|---|
| Amitriptyline | Elavil |
| Nortriptyline | Pamelor |
| Imipramine | Tofranil |
| Desipramine | Norpramin |
| Clomipramine | Anafranil |
| Doxepin | Sinequan |
| Trimipramine | Surmontil |
| Dosulepin (Dothiepin) | Prothiaden |
| Lofepramine | Gamanil |
| Amineptine | (withdrawn - opioid-like TCA, most mechanistically similar to tianeptine) |
Note: Amineptine is the TCA most pharmacologically similar to tianeptine - both are atypical TCAs with dopamine/opioid-linked mechanisms. Amineptine was withdrawn from the market due to abuse.
4. Monoamine Oxidase Inhibitors (MAOIs)
Reserved for treatment-resistant depression; significant dietary and drug interaction risks.
| Drug | Brand Name |
|---|---|
| Phenelzine | Nardil |
| Tranylcypromine | Parnate |
| Isocarboxazid | Marplan |
| Selegiline (transdermal) | Emsam |
| Moclobemide | Manerix (reversible MAOI; not available in US) |
5. Atypical Antidepressants (Diverse Mechanisms)
| Drug | Brand Name | Mechanism |
|---|---|---|
| Bupropion | Wellbutrin | Norepinephrine-dopamine reuptake inhibitor (NDRI) |
| Mirtazapine | Remeron | NaSSA - alpha-2 antagonist + 5-HT2/5-HT3 blocker |
| Trazodone | Oleptro | Serotonin antagonist and reuptake inhibitor (SARI) |
| Nefazodone | (generic) | SARI; hepatotoxicity risk |
| Agomelatine | Valdoxan | Melatonin MT1/MT2 agonist + 5-HT2C antagonist |
| Vortioxetine | Trintellix | Serotonin modulator and stimulator (SMS) |
| Vilazodone | Viibryd | SSRI + 5-HT1A partial agonist |
| Gepirone | Exxua | 5-HT1A partial agonist (buspirone-related; FDA approved 2023) |
6. Augmentation / Adjunct Agents for Depression
Used when primary antidepressants are partially effective.
| Drug | Brand Name | Class |
|---|---|---|
| Aripiprazole | Abilify / Opipza | Atypical antipsychotic |
| Brexpiprazole | Rexulti | Atypical antipsychotic |
| Quetiapine XR | Seroquel XR | Atypical antipsychotic |
| Cariprazine | Vraylar | Atypical antipsychotic |
| Lithium | Eskalith | Mood stabilizer |
| Lamotrigine | Lamictal | Anticonvulsant/mood stabilizer |
| Buspirone | Buspar | 5-HT1A partial agonist (anxiety only) |
7. Treatment-Resistant Depression Agents
| Drug | Brand Name | Mechanism |
|---|---|---|
| Esketamine | Spravato | NMDA glutamate receptor antagonist (intranasal) |
| Ketamine (racemic) | Ketalar | NMDA antagonist (IV infusion, off-label) |
| Dextromethorphan/bupropion | Auvelity | NMDA antagonist + NDRI |
| Zuranolone | Zurzuvae | GABA-A positive allosteric modulator (postpartum depression) |
| Brexanolone | Zulresso | GABA-A modulator (IV; postpartum depression) |
8. Anxiolytics (for the Anxiety Component of Tianeptine's Indications)
| Drug | Brand Name | Class |
|---|---|---|
| Diazepam, lorazepam, alprazolam, clonazepam | Various | Benzodiazepines |
| Buspirone | Buspar | 5-HT1A agonist |
| Hydroxyzine | Vistaril | Antihistamine anxiolytic |
| Pregabalin | Lyrica | Alpha-2-delta calcium channel ligand |
| Gabapentin | Neurontin | Alpha-2-delta ligand (off-label for anxiety) |
Where Tianeptine Fits
Tianeptine sits in an unusual position - listed among TCAs but mechanistically distinct. It does not block monoamine reuptake; instead it acts as a mu-opioid receptor agonist and AMPA receptor modulator. The closest mechanistic parallels among approved drugs are:
- Esketamine/ketamine (glutamate modulation for depression)
- Amineptine (TCA with dopaminergic/opioid tendencies - now withdrawn)
- Buprenorphine (opioid receptor activity, studied off-label for depression)
Tianeptine itself is not FDA-approved in the United States, and as of 2025 multiple states have scheduled it as a controlled substance due to its abuse potential at high doses.
- Tintinalli's Emergency Medicine
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
- Kaplan & Sadock's Comprehensive Textbook of Psychiatry
- Stahl's Essential Psychopharmacology
- Systematic review: Approved psychiatric medications for depressive disorders 2009-2025 (PMC12506068)
This is a shared conversation. Sign in to Orris to start your own chat.